In breast cancer, IL-6 is known to activate STAT3, which has been shown to be an important signaling molecule that is associated with an unfavorable prognosis; in fact, the principal mechanism of STAT3 activation is via the IL-6/gp130/Jak pathway [50]. This evidence concerns the gene STAT3 and breast cancer.